Frontierby eninvs

Language: EN · RU

← Region

Sun Pharmaceutical Industries (SUNPHARMA) INR

At a glance: strengths & risks
✓Revenue growing (+12%)✓Net cash balance sheet

Sector: Pharmaceuticals

IN_SUNPHARMA

Price chart

1 929 INRDay 0.47%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
1 929 INR · 0.47%
Market cap
4628.2 bn INR

Growth

Δ revenue y/y
10.1%
Δ EBITDA y/y
5.5%

Multiples

P/E (LTM)
40.3x
3y avg: 38.6x
P/B (FY)
5.5x
P/E (ann.)
40.0x
EV/EBITDA (LTM)
27.7x
3y avg: 27.2x
EV/EBITDA (ann.)
26.6x

Cash return

Dividend yield
0.8%
FCF yield (LTM)
1.9%

Value creation

fundamental value/yr, % of market cap
Value created / year
+3.0%
↓ details

Liquidity

Daily turnover (listing)
496.1 mln INR

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B INR, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB INROperating profitB INRD&AB INREBITDAB INRNet profitB INROperating CFB INRCapex + M&AB INRAssetsB INREquityB INRROE (annualized)Net debtB INRSource
2026-06-30Q2 2026 (3M)PARTIAL151.8
y/y 10.1%
35.6
y/y 5.5%
7.4
y/y 5.4%
43.0
y/y 5.5%
28.9
y/y 27.0%
———
y/y —
838.8
y/y 15.7%
13.8%≈ -56.9—
2026-03-31FY 2026 (12M)OK—
y/y 11.9%
—
y/y 8.1%
—
y/y 14.1%
—
y/y 9.1%
—
y/y 5.0%
——1087.9
y/y 18.1%
835.7
y/y 15.7%
14.2%-56.9—
2025-12-31Q4 2025 (3M)PARTIAL154.7
y/y 13.1%
40.6
y/y 14.0%
7.3
y/y —
47.9
y/y 34.6%
33.7
y/y 16.0%
———
y/y —
781.3
y/y 12.6%
5.7%≈ -75.7—
2025-09-30Q3 2025 (3M)OK144.8
y/y 8.9%
33.7
y/y 5.7%
2.4
y/y —
36.1
y/y 13.2%
31.2
y/y 2.6%
——1037.1
y/y 17.7%
781.3
y/y 12.6%
16.6%-75.7Link
2025-06-30Q2 2025 (3M)PARTIAL137.9
y/y 9.0%
33.7
y/y 12.3%
7.0
y/y —
40.7
y/y 35.6%
22.8
y/y -19.6%
———
y/y —
724.9
y/y 8.0%
12.6%≈ -84.0—
2025-03-31FY 2025 (12M)OK—
y/y 9.0%
—
y/y 20.2%
—
y/y 0.7%
—
y/y 16.4%
—
y/y 14.1%
——921.0
y/y 7.7%
722.2
y/y 13.4%
15.4%-84.0—
2024-12-31Q4 2024 (3M)PARTIAL136.8
y/y 10.5%
35.6
y/y 30.5%
—
y/y —
35.6
y/y 30.5%
29.0
y/y 15.0%
———
y/y —
693.8
y/y 9.8%
5.6%≈ -69.3Link
2024-09-30Q3 2024 (3M)OK132.9
y/y 9.0%
31.8
y/y 23.4%
—
y/y —
31.8
y/y 23.4%
30.4
y/y 28.0%
——881.2
y/y 10.9%
693.8
y/y 9.8%
17.8%-69.3Link
2024-06-30Q2 2024 (3M)PARTIAL126.5
y/y —
30.0
y/y —
—
y/y —
30.0
y/y —
28.4
y/y —
———
y/y —
671.1
y/y —
17.3%≈ -64.4Link
2024-03-31FY 2024 (12M)OK—
y/y 10.4%
—
y/y 12.8%
—
y/y 1.0%
—
y/y 10.3%
—
y/y 13.0%
——855.0
y/y 5.9%
636.7
y/y 13.7%
15.1%-64.4—
2023-12-31Q4 2023 (3M)PARTIAL123.8
y/y —
27.3
y/y —
—
y/y —
27.3
y/y —
25.2
y/y —
———
y/y —
632.0
y/y —
5.3%≈ 15.7Link
2023-09-30Q3 2023 (3M)OK121.9
y/y —
25.8
y/y —
—
y/y —
25.8
y/y —
23.8
y/y —
——794.4
y/y —
632.0
y/y —
15.9%≈ 15.7Link
2023-03-31FY 2023 (12M)OK432.8
y/y —
92.8
y/y —
25.3
y/y —
118.1
y/y —
84.7
y/y —
49.6-20.9807.4
y/y —
560.0
y/y —
—15.7—

Revenue & EBITDA

RevenueEBITDA

Quarterly values (INR mln)

050 000100 000150 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

0%10%20%30%40%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

Net debt / cash (INR mln)

-100 000-80 000-60 000-40 000-20 00002024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q22026 q4

Profit and cash

Profit is cash-backed
In a typical year of 2022–2026 operating cash flow came to 1.27x of reported net profit; after capex, 1.04x.
year20222023202420252026
cash flow / profit2.75x0.58x1.27x1.29x1.08x
accruals, % of assets—4.3%-3.0%-3.4%-0.9%
net debt / EBITDA -0.3x · capex 0.9x of depreciation
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: +3.0%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (42 957 − 40 726) × 3.78
8 424
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (4 628 211 + -56 889) ÷ 162 233
28.2x
3. Target multiple
(Current EV/EBITDA + 11) ÷ 2
= (28.2 + 11) ÷ 2
19.6x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -27 102 + 0 + 0 − 0
-27 102
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (8 424 × 19.6 + -27 102) ÷ 4 628 211
+3.0%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • FCF (LTM) approximated by latest FY (ended 2026-03-31, before the latest reported period 2026-06-30)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only

Revenue growth & acceleration

Growth steady →
Last-year revenue growth +12% vs +9% the year before — a +2.9 pp move. 3-year CAGR +10%.
revenue growth by year: 2024 +10% · 2025 +9% · 2026 +12%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-07-075 INREx-dividend: 5 INR per sharePaidYahoo Finance (ex-div)
2026-02-0511 INREx-dividend: 11 INR per sharePaidYahoo Finance (ex-div)
2025-07-075.5 INREx-dividend: 5.5 INR per sharePaidYahoo Finance (ex-div)
2025-02-0610.5 INREx-dividend: 10.5 INR per sharePaidYahoo Finance (ex-div)
2024-07-125 INREx-dividend: 5 INR per sharePaidYahoo Finance (ex-div)
2024-02-098.5 INREx-dividend: 8.5 INR per sharePaidYahoo Finance (ex-div)
2023-07-284 INREx-dividend: 4 INR per sharePaidYahoo Finance (ex-div)
2023-02-087.5 INREx-dividend: 7.5 INR per sharePaidYahoo Finance (ex-div)
2022-08-193 INREx-dividend: 3 INR per sharePaidYahoo Finance (ex-div)
2022-02-097 INREx-dividend: 7 INR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Sun Pharmaceutical Industries (SUNPHARMA) — from primary filings.

Frequently asked questions

What is Sun Pharmaceutical Industries (SUNPHARMA)'s P/E ratio?
Sun Pharmaceutical Industries (SUNPHARMA) trades at a P/E of 40.3x (price to trailing 12-month earnings).
What is Sun Pharmaceutical Industries (SUNPHARMA)'s EV/EBITDA?
Sun Pharmaceutical Industries (SUNPHARMA) trades at 27.7x EV/EBITDA.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s P/B ratio?
Sun Pharmaceutical Industries (SUNPHARMA) trades at a P/B of 5.5x.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s dividend yield?
Sun Pharmaceutical Industries (SUNPHARMA)'s trailing 12-month dividend yield is 0.8%.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s return on equity (ROE)?
Sun Pharmaceutical Industries (SUNPHARMA)'s ROE is 13.8%.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s market capitalization?
Sun Pharmaceutical Industries (SUNPHARMA)'s market cap is 4628.2 bn INR.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map